Xin Lang Cai Jing·2025-11-12 11:28Core Viewpoint - BeiGene has announced an increase in funding for its drug clinical trial research project, utilizing remaining over-raised funds of 163.15 million yuan, extending the project deadline to December 31, 2026 [1][3]. Fund Utilization Overview - BeiGene completed its A-share IPO in December 2021, raising a total of 22.15964 billion yuan, with a net amount of 21.63015 billion yuan after deducting issuance costs. As of June 30, 2025, the company has utilized 19.65094 billion yuan of the raised funds [2]. - The specific allocation of the raised funds includes various projects, with the drug clinical trial research project being a significant focus [2]. Increased Investment Details - The additional funding will be directed entirely towards "preclinical research costs" within the drug clinical trial research project, which encompasses various stages of drug development [3]. - The total planned investment for the project will increase from 13.24594 billion yuan to 13.40909 billion yuan, while the overall project investment remains unchanged at 15.2807 billion yuan [3]. R&D Strategy and Importance - BeiGene emphasizes that continuous investment in R&D is crucial for maintaining its technological advantage as a leading global oncology innovation company. The company has established a comprehensive R&D system covering various fields, including molecular targeted drugs and immuno-oncology therapies [4]. - The new funding will focus on preclinical research, including expenses for reagents, equipment, facility rentals, and personnel, enhancing the company's independent R&D platform and system [4].